WO2007034012A3 - Method of obtaining amorphous calcium atorvastatin - Google Patents

Method of obtaining amorphous calcium atorvastatin Download PDF

Info

Publication number
WO2007034012A3
WO2007034012A3 PCT/ES2006/000517 ES2006000517W WO2007034012A3 WO 2007034012 A3 WO2007034012 A3 WO 2007034012A3 ES 2006000517 W ES2006000517 W ES 2006000517W WO 2007034012 A3 WO2007034012 A3 WO 2007034012A3
Authority
WO
WIPO (PCT)
Prior art keywords
amorphous calcium
oxo
phenyl
atorvastatin
obtaining amorphous
Prior art date
Application number
PCT/ES2006/000517
Other languages
Spanish (es)
French (fr)
Other versions
WO2007034012A2 (en
Inventor
Genoves Montserrat Faja
Llorens Jaume Vilarrasa
Dominguez Ramon Asensio
Chapinal Fernando Garcia
Rodriguez Ma Carmen Cruzado
Original Assignee
Ercros Ind Sa
Genoves Montserrat Faja
Llorens Jaume Vilarrasa
Dominguez Ramon Asensio
Chapinal Fernando Garcia
Rodriguez Ma Carmen Cruzado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ercros Ind Sa, Genoves Montserrat Faja, Llorens Jaume Vilarrasa, Dominguez Ramon Asensio, Chapinal Fernando Garcia, Rodriguez Ma Carmen Cruzado filed Critical Ercros Ind Sa
Publication of WO2007034012A2 publication Critical patent/WO2007034012A2/en
Publication of WO2007034012A3 publication Critical patent/WO2007034012A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The invention relates to a novel method of obtaining amorphous calcium atorvastatin from N-phenyl-2-[1-phenyl-2-(4-fluorophenyl)-2-oxo]ethyl-4-methyl-3-oxo-pentanamide (II) and (3R,5R)-7-amino-3,5-(O- isopropylidene)dihydroxy-heptanoate of terc-butyl (III), by reacting same with toluene reflux in the presence of an acid catalyst, using a series of synthesis, isolation and hydrolysis steps, after which the crude amorphous atorvastatin obtained is purified, isolated and dried, said steps being performed under very smooth reaction conditions using very short reaction times, moderate temperatures and minimal amounts of reagents, thereby producing a high-quality product.
PCT/ES2006/000517 2005-09-15 2006-09-14 Method of obtaining amorphous calcium atorvastatin WO2007034012A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200502251 2005-09-15
ES200502251A ES2270722B1 (en) 2005-09-15 2005-09-15 PROCEDURE FOR OBTAINING ATORVASTATIN CALCICA AMORFA.

Publications (2)

Publication Number Publication Date
WO2007034012A2 WO2007034012A2 (en) 2007-03-29
WO2007034012A3 true WO2007034012A3 (en) 2007-05-18

Family

ID=37889165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2006/000517 WO2007034012A2 (en) 2005-09-15 2006-09-14 Method of obtaining amorphous calcium atorvastatin

Country Status (2)

Country Link
ES (1) ES2270722B1 (en)
WO (1) WO2007034012A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082362A1 (en) * 2007-11-05 2009-07-02 Ulkar Kimya San. Ve Tic. A.S. A method for producing statins in pure form
CN116102482A (en) * 2022-08-17 2023-05-12 重庆普佑生物医药有限公司 Preparation method of atorvastatin calcium

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330172A2 (en) * 1988-02-22 1989-08-30 Warner-Lambert Company Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
WO2002059087A1 (en) * 2001-01-23 2002-08-01 Lek Pharmaceutical And Chemical Company D.D. Preparation of non-crystalline atorvastatin calcium
WO2002083637A1 (en) * 2001-04-11 2002-10-24 Cadila Healthcare Limited Process for the production of amorphous atorvastatin calcium
WO2004085391A1 (en) * 2003-03-24 2004-10-07 Richter Gedeon Vegyészeti Gyár Rt. Process for the synthesis of amorphous atorvastatin calcium
US20050090542A1 (en) * 2000-11-30 2005-04-28 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US20050131055A1 (en) * 2002-02-01 2005-06-16 Leciva, A.S. Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7-3-phenly-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (actorvastatin)
WO2005092852A1 (en) * 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330172A2 (en) * 1988-02-22 1989-08-30 Warner-Lambert Company Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US20050090542A1 (en) * 2000-11-30 2005-04-28 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002059087A1 (en) * 2001-01-23 2002-08-01 Lek Pharmaceutical And Chemical Company D.D. Preparation of non-crystalline atorvastatin calcium
WO2002083637A1 (en) * 2001-04-11 2002-10-24 Cadila Healthcare Limited Process for the production of amorphous atorvastatin calcium
US20050131055A1 (en) * 2002-02-01 2005-06-16 Leciva, A.S. Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7-3-phenly-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (actorvastatin)
WO2004085391A1 (en) * 2003-03-24 2004-10-07 Richter Gedeon Vegyészeti Gyár Rt. Process for the synthesis of amorphous atorvastatin calcium
WO2005092852A1 (en) * 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form

Also Published As

Publication number Publication date
WO2007034012A2 (en) 2007-03-29
ES2270722A1 (en) 2007-04-01
ES2270722B1 (en) 2008-03-01

Similar Documents

Publication Publication Date Title
WO2007140195A3 (en) Methods and systems for increasing production of equilibrium reactions
WO2007089527A3 (en) Method of forming a dianhydrosugar alcohol
WO2009092793A3 (en) Method for fermentatively producing 1,5-diaminopentane
TW200726754A (en) Chemical process
DE602004024964D1 (en) PROCESS FOR THE PREPARATION OF ALCOHOL
WO2008076747A3 (en) Processes of producing fermentation products
CZ20031946A3 (en) Novel synthesis process of atorvastatin and phenylboronate as intermediate compounds
WO2010014148A3 (en) Ethylene production from acetic acid utilizing dual reaction zone process
WO2008089984A3 (en) Process for the preparation of ezetimibe and derivatives thereof
WO2007030405A3 (en) A process for preparing ester oxazolidine compounds and their conversion to florfenicol
TW200633974A (en) Method for producing aromatic carbonate
WO2010099441A3 (en) Synthesis of molecular sieve ssz-74 using a hydroxide-mediated gel
WO2009084862A3 (en) Catalyst composition including zirconium compounds for esterfication reaction and method for preparing ester compounds
WO2005075392A3 (en) Production process of 3-alkoxy-1-propanols, and 3-alkoxy-1-propanols obtained by the production process
WO2006124793A3 (en) Catalytically activated vacuum distillation system
WO2008099882A1 (en) 2-methyl-3-(3,4-methylenedioxyphenyl)propanal, and method for production thereof
WO2009054356A1 (en) PROCESS FOR PRODUCTION OF CYANOHYDRIN COMPOUND, AND PROCESS FOR PRODUCTION OF α-HYDROXYESTER COMPOUND
WO2007034012A3 (en) Method of obtaining amorphous calcium atorvastatin
WO2007003200A3 (en) High yield synthesis methods for producing organic salts of strontium
WO2008142333A3 (en) Method for the synthesis of heterogeneous palladium catalysts, catalysts obtained and use of same
WO2009099291A3 (en) Potassium organotrifluoroborate derivative and a production method therefor
WO2004085048A3 (en) Production of 5-methyl-n-(methyl aryl)-2-pyrrolidone, 5-methyl-n-(methyl cycloalkyl)-2-pyrrolidone and 5- methyl-n-alkyl-2-pyrrolidone by reductive amination of leuvlinic acid esters with cyano compounds
MX2007005603A (en) Method for producing trimethylcyclododecatriene.
DE602006009015D1 (en) for their production.
WO2006098855A3 (en) Processes for preparing morphinans and intermediates thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06819981

Country of ref document: EP

Kind code of ref document: A2